Long-term safety and efficacy of the fully human CAR-T therapy CT103A in relapsed/refractory multiple myeloma.
Yu Q, Wang D, Li Z, An N, Li C, Bao Y, Wen X, Long X, Wang J, Jiang L, Mu W, Zhang P, Shu C, Ye H, Gui H, Cai S, Hu G, Wang W, Du A, Li C.
Yu Q, et al. Among authors: hu g.
Mol Ther. 2024 Nov 8:S1525-0016(24)00740-8. doi: 10.1016/j.ymthe.2024.11.013. Online ahead of print.
Mol Ther. 2024.
PMID: 39520053
Free article.